Literature DB >> 25655015

Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.

William R Lenderking1, Sally Mannix, Jennifer Petrillo, Christopher Kenney, Amanda Landrian, Anette-Eleonore Schrag.   

Abstract

BACKGROUND AND OBJECTIVES: The 26-item Parkinson disease dyskinesia scale (PDYS-26) was developed to assess the impact of Parkinson's disease levodopa-induced dyskinesias (PD-LID). The purpose of this qualitative research study was to assess the content validity of the PDYS-26 in an independent sample and to use the findings to suggest a conceptual framework around the impact of PD-LID.
METHODS: PD patients experiencing LID and their caregivers were recruited from four US clinical sites. Stage I involved 22 qualitative concept elicitation interviews with patients and caregivers, and 11 qualitative cognitive interviews (CI) with patients about the PDYS-26. The PDYS-26 was modified based on Stage I findings. Stage II consisted of 13 CI on the Modified PDYS.
RESULTS: Forty-six participants were interviewed across both stages of the study. Patient mean age was 67.3 (SD ± 9.55) years; 19 (54.3 %) female; 34 (97.1 %) white. The content validity of the PDYS-26 was generally supported. A revised conceptual framework with three hypothesized domains (body control, activities of daily living, social consequences) was developed. Modifications were made to the PDYS-26 (i.e., emphasizing LID in the instructions; response scale modification; deleting or modifying items), which resulted in the 22-item Modified PDYS.
CONCLUSIONS: Stage I and II findings suggested a number of modifications to the scale in order to improve the content validity. Psychometric testing of the revised scale with a larger patient sample is suggested to evaluate item performance, establish scoring, and provide quantitative support for the conceptual framework.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25655015     DOI: 10.1007/s11136-015-0925-7

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  22 in total

1.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

Authors:  A Schrag; N Quinn
Journal:  Brain       Date:  2000-11       Impact factor: 13.501

2.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-13       Impact factor: 5.725

Review 3.  Parkinson's disease and movement disorders: moving forward.

Authors:  Joseph Jankovic
Journal:  Lancet Neurol       Date:  2008-01       Impact factor: 44.182

4.  PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures.

Authors:  V Peto; C Jenkinson; R Fitzpatrick
Journal:  J Neurol       Date:  1998-05       Impact factor: 4.849

Review 5.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

6.  Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease.

Authors: 
Journal:  Arch Neurol       Date:  2001-10

7.  Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

Authors:  John G Nutt; Kathy A Chung; Nicholas H G Holford
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

Review 8.  Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.

Authors:  Elmyra V Encarnacion; Robert A Hauser
Journal:  Eur Neurol       Date:  2008-05-15       Impact factor: 1.710

Review 9.  Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.

Authors:  Carlo Colosimo; Pablo Martínez-Martín; Giovanni Fabbrini; Robert A Hauser; Marcelo Merello; Janis Miyasaki; Werner Poewe; Cristina Sampaio; Olivier Rascol; Glenn T Stebbins; Anette Schrag; Christopher G Goetz
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

Review 10.  Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments.

Authors:  Panagiotis Bargiotas; Spyridon Konitsiotis
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-22       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.